PeptAI

Raised $50,000. Trading fees have paid the project $112,000 so far.

An agent fleet that designs peptides, validates them computationally, and books its own wet-lab work. First launch on the coin-to-company framework.

peptai

Built in-house at Bio. Included here because every number is visible.

The problem

Peptide discovery moves at the speed of its handoffs. Discovery to synthesis to CRO, each one behind a contracting cycle, each cycle slower than the science it's gating.

The raise

DateWhat happenedAmount
1 May 2026Ignition Sale opens
14 May 2026Sale closes, >10x oversubscribed on >1M USDC from 650+ participants$50,000
Released to the project at launch$25,000
Liquidity pool$25,000

Starting FDV $1,000,000.

What it paid for

Agent-01, GLP-1R. Thirty-five candidates advancing.

Agent-02, KISS1R. Two of ten through to the final gate.

Agent-03, OX2R. Lead candidate ready for wet lab. This one produced OX2R-004. Every approved orexin drug is an antagonist for insomnia. Agent-03 went after an agonist for ADHD, where low orexin shows up in drug-naive patients. Design took 24 hours.

The pipeline itself. Wet lab runs at Adaptyv Bio, paid machine to machine. Every gate decision, every pass, every failure publishes on Molecule Labs where anyone can check it.

What token holders get

PeptAI is the first launch built on the coin-to-company framework. Governance tokens carry a defined route to convert into equity as the company matures, so the people who back the science at the earliest stage hold something that follows the company forward.

Where they are now

VolumeFees paid to the project
First 24 hours$8.27M$58,800
First two weeks$9.05M$65,800
To date$112,000

Against a $50,000 raise, 2.24x has come back. In USDC. The tokens didn't dilute anyone and the fees don't depend on where the price goes.

Two things about the shape. Almost 90% of that first fortnight arrived on day one. Since then roughly $46,000 has accrued over twelve weeks, about $3,700 a week, still coming in.

Start a conversation

Michele Gallia, Head of Business Development

michele@bio.xyz · Contact form

Sources: Bio Protocol Ignition Sale announcement 1 May 2026; app.bio.xyz/agents/peptai; internal fee and volume data; exchange reporting on TGE 14 May 2026.

LAUNCHED ON BIO
Peptai logo

Peptai

PeptAI is an autonomous AI agent that discovers new peptide drug candidates. It designs peptides computationally, then pushes them through an 8-gate validation pipeline. Every result is published on-chain (blockchain) so anyone can verify the science. Once a candidate passes validation, it's sent to the wet-lab for synthesis and binding assays. PeptAI is receptor agnostic, however first programmes target GLP1R, KISS1R, OX2R and several other GPCRs.

Contact

Tell us what you're building.

Share a few details and we'll pass your request to the right person on the team.
Loading role options…

You may unsubscribe at any time using the link in our newsletter. Read our Privacy Policy to learn how we protect your data. By clicking submit below, you consent to allow Bio Protocol to store and process the personal information submitted above to respond to your enquiry.

Contact form status updates appear here.